Shares of GlobeImmune, Inc. (OTCMKTS:GBIM) Tank Following Announced Updates

GlobeImmune, Inc. (OTCMKTS:GBIM) announce several company updates.

LOUISVILLE, CO–(Marketwired – November 17, 2016) – GlobeImmune, Inc. today provided an update on the Company’s business:

    Gilead Sciences, Inc. has terminated the collaboration and license agreement with the Company and its rights to GS-4774 have been returned to GlobeImmune;

    Timothy C. Rodell has resigned his positions as the Company’s Chief Executive Officer and President but remains on the Board of Directors;

  1. Jeffrey Dekker has been appointed as the Company’s President, Secretary and Treasurer and been named to the Company’s Board of Directors;
  2. William Freytag, Augustine J. Lawlor, Dan J. Mitchell and S. Edward Torres have resigned from the Company’s Board of Directors; and

    The Company has terminated the lease for 40,000 gross square feet of office, laboratory and manufacturing space which formerly served as the Company’s corporate headquarters.

In July 2016, GlobeImmune filed to voluntarily delist the Company’s outstanding Common Stock from The NASDAQ Capital Market and deregistered the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company also terminated the Company’s reporting obligations under Sections 13(a) and 15(d) of the Exchange Act and deregistered its Common Stock under Section 12(g) of the Exchange Act. The Company is no longer required to file annual, periodic and current reports with the SEC or release any other information. The Company does not plan to publicly release any further information about its operations or business.

Original Source


GlobeImmune, Inc. (OTCMKTS:GBIM) shares are trading -42.45% on the news and in the range of $0.35 – 0.64 during the current trading session.  When taking a look at which direction the stock might be headed, investors often look to brokerage analysts who cover the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.

Are Shares of GlobeImmune, Inc. (OTCMKTS:GBIM) Ready to Explode?  Sign up to our Newsletter to be the First to Know 

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where the stock is trading on a technical level, the stock is trading -65.06% away from its 50-day moving average of $1.14.  Based on the most recent available data, the equity is -93.65% off of its 52-week high of $6.30 and +14.61% away from its 52-week low which is $0.35.

Today, the stock opened at $0.60 and the last bid at the time of writing stood at $0.40.  During the session thus far, the equity dipped down to $0.35 and touched $0.64 as the high point.  GlobeImmune, Inc. (OTCMKTS:GBIM) has a market cap of $2.30B and has seen an average daily volume of 56,032 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below. 

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Related posts

Leave a Comment